Mohamed, A., Kawana, K., Karam, S. (2019). EFFECT OF FLUOXETINE ON THE STRUCTURE OF ALVEOLAR BONE IN RATS WITH DEPRESSION. test, 44(3), 82-88. doi: 10.21608/adjalexu.2019.63563
Aya S. Mohamed; Khadiga Y. Kawana; Sahar S. Karam. "EFFECT OF FLUOXETINE ON THE STRUCTURE OF ALVEOLAR BONE IN RATS WITH DEPRESSION". test, 44, 3, 2019, 82-88. doi: 10.21608/adjalexu.2019.63563
Mohamed, A., Kawana, K., Karam, S. (2019). 'EFFECT OF FLUOXETINE ON THE STRUCTURE OF ALVEOLAR BONE IN RATS WITH DEPRESSION', test, 44(3), pp. 82-88. doi: 10.21608/adjalexu.2019.63563
Mohamed, A., Kawana, K., Karam, S. EFFECT OF FLUOXETINE ON THE STRUCTURE OF ALVEOLAR BONE IN RATS WITH DEPRESSION. test, 2019; 44(3): 82-88. doi: 10.21608/adjalexu.2019.63563

EFFECT OF FLUOXETINE ON THE STRUCTURE OF ALVEOLAR BONE IN RATS WITH DEPRESSION

Alexandria Dental Journal
Article 16, Volume 44, Issue 3, December 2019, Pages 82-88    PDF (778.08 K)
Document Type: Original Article
DOI: 10.21608/adjalexu.2019.63563
Authors
Aya S. Mohamed* 1; Khadiga Y. Kawana2; Sahar S. Karam3
1Demonstrator of Oral Biology 2014, Faculty of Dentistry, Alexandria University, Egypt.
2Professor of Oral Biology, Faculty of Dentistry, Alexandria University, Egypt
3Professor of Oral Biology, Head of Department oral Biology, Faculty of Dentistry, Alexandria University, Egypt
Abstract
INTRODUCTION: Depression is one of the most prevalent psychological disorders. It affects all body systems including endocrinal,
neurological and immune system. Additionally, it is thought to affect bone homeostasis. Antidepressants are the most commonly prescribed
drugs. They are classified into tricyclic and tetra cyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and selective
serotonin-reuptake inhibitors (SSRIs). Fluoxetine, which is a selective serotonin-reuptake inhibitor, is used for the treatment of depression by
selectively acting on serotonin (5-HT). Fluoxetine plays a major role in bone apposition and in maintaining the bone homeostasis.
OBJECTIVES: To investigate the effect of selective serotonin-reuptake inhibitor (fluoxetine) on the structure of alveolar bone in rats with
induced depression.
MATERIALS AND METHODS: Thirty adult male rats were divided as follows: Group I: (control group) which consists of 10 rats, Group < br />II: (depression group) 10 rats were exposed to chronic unpredictable stress (CUS) to induce depression, Group III: (fluoxetine group) 10 rats
were exposed to chronic unpredictable stress (CUS) to induce depression and at the same time they were orally supplied with 10 mg/kg/day of
fluoxetine. After 3 months, the mandibles were dissected out and prepared for histological analysis using light microscope, scanning electron
microscope (SEM) and energy dispersive x-ray microanalysis (EDX).
RESULTS: In the control group, the alveolar bone surface showed a regular and smooth outline. In the depression group, there was a significant
disturbance in the bone architecture. The bone surface showed an irregular outline with multiple osteoclasts lying in How ship's lacunae. Deeply
stained incremental lines were also evident. In the fluoxetine group, the bone surface restored its regular outline with multiple osteoblasts and
osteocytes. The bone showed incremental lines indicating bone formation.
CONCLUSIONS: Depression can lead to bone loss and osteoporosis. Fluoxetine is an effective drug in enhancing the bone condition and
restoring the normal architecture of the alveolar bone.
Keywords
serotonin; selective serotonin-reuptake inhibitor; alveolar bone; depression
References
  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Arlington: American Psychiatric Pub; 2013.
  2. Nestler EJ, Gould E, Manji H. Preclinical models: status of basic research in depression. Biol Psychiatry.2002;52:503- 28.
  3. Pasco JA, Jacka FN, Williams LJ, Henry MJ, Nicholson GC, Kotowicz MA, et al. Leptin in depressed women: crosssectional and longitudinal data from an epidemiologic study. J Affect Disord.2008;107:221-5.
  4. Sadock BJ, Sadock VA. Kaplan & Sadock's concise textbook of clinical psychiatry. 3rd ed. Philadelphia, New York, London: Lippincott Williams & Wilkins; 2008.
  5. Beekman AT, Deeg DJ, van Tilburg T, Smit JH, Hooijer C, van Tilburg W. Major and minor depression in later life: a study of prevalence and risk factors. J Affect Disord.1995;36:65-75.
  6. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry.1990;47:411-8.
  7. Ruddell RG, Mann DA, Ramm GA. The function of serotonin within the liver. J Hepatol. 2008;48:666-75.
  8. Banović M, Bordukalo-Nikšić T, Balija M, Čičin-Šain L, Jernej B. Platelet serotonin transporter (5HTt): physiological influences on kinetic characteristics in a large human population. Platelets.2010;21:429-38.
  9. Richter T, Paluch Z, Alusik S. The non-antidepressant effects of citalopram: a clinician’s perspective. Neuro Endocrinol Lett.2014;35:7-12.
  10. Cacabelos R. World guide for drug use and pharmacogenomics. 1st ed. Bergondo: Euro Espes Publishing; 2014.
  11. El-Demerdash E, Mohamadin AM. Does oxidative stress contribute in tricyclic antidepressants-induced cardiotoxicity? Toxicol Lett.2004;152:159-66.
  12. Izumi T, Iwamoto N, Kitaichi Y, Kato A, Inoue T, Koyama T. Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5- HT-related behavior in rats. Eur J Pharmacol.2006;532:258-64.
  13. Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007;68:35-41. 14.Newman SC, Schopflocher D. Trends in antidepressant prescriptions among the elderly in Alberta during 1997 to 2004. Can J Psychiatry.2008;53:704-7.
  14. Tuccori M, Testi A, Antonioli L, Fornai M, Montagnani S, Ghisu N, et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther.2009;31:1426-53.
  15. Gustafsson BI, Westbroek I, Waarsing JH, Waldum H, Solligård E, Brunsvik A, et al. Long‐term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. J Cell Biochem. 2006;97:1283-91.
  16. Mortazavi SH, Khojasteh A, Vaziri H, Khoshzaban A, Roudsari MV, Razavi SH. The effect of fluoxetine on bone regeneration in rat calvarial bone defects. Oral Surg, Oral Med, Oral Pathol, Oral Radiol, and Endod. 2009;108:22-7.
  17. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochemical and biophysical research communications. 1999;256:449-55.
  18. Battaglino R, Vokes M, Schulze‐Späte U, Sharma A, Graves D, Kohler T et al. Fluoxetine treatment increases trabecular bone formation in mice. J Cell Biochem. 2007;100:1387-94.
  19. Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH. Inhibition of the serotonin (5- hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology. 2005;146:685-93.
  20. Monteiro S, Roque S, de Sá-Calçada D, Sousa N, CorreiaNeves M, Cerqueira JJ. An efficient chronic unpredictable stress protocol to induce stress-related responses in C57BL/6 mice. Front Psychiatry.2015;6:6.
  21. Dulawa SC, Holick KA, Gundersen B, Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology.2004;29:1321-30.
  22. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc. 2007;2:322-8.
  23. Can A, Dao DT, Arad M, Terrillion CE, Piantadosi SC, Gould TD. The mouse forced swim test. J Vis Exp.2012;59:e3638.
  24. Orban BJ, Bhaskar SN. Oral histology and embryology. 11th ed. Saint Louis: Mosby; 1991.
  25. Goldstein J, Newdury D, Joy D, Lyman C, Echlin P. Scanning electron microscope and X-ray analysis. 3rd ed. New York: Kluwer Academic/ Plenum publishers; 2003.
  26. Schatzberg AF, Nemeroff CB. The American Psychiatric Association Publishing Textbook of Psychopharmacology. 5th ed. United States: American Psychiatric Pub; 2017.
  27. Kapoor D, Jones TH. Smoking and hormones in health and endocrine disorders. Eur J Endocrinol 2005;152:491-9.
  28. Nanci A. Ten Cate's Oral Histology-E-Book: Development, Structure, and Function. 9th ed. St. Louis: Elsevier Health Sciences; 2017.
  29. Wu Q, Magnus JH, Liu J, Bencaz AF, Hentz JG. Depression and low bone mineral density: a meta-analysis of epidemiologic studies. Osteoporos Int.2009;20:1309-20.
  30. Elefteriou F. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys.2008;473:231-6.
  31. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry. 2008;13:717.
  32. Adler UC, Marques AH, Calil HM. Inflammatory aspects of depression. Inflamm Allergy Drug Targets.2008;7:19- 23.
  33. Warden SJ, Bliziotes MM, Wiren KM, Eshleman AJ, Turner CH. Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol Cell Endocrinol. 2005;242:1-9.
  34. Gustafsson BI, Thommesen L, Stunes AK, Tommeras K, Westbroek I, Waldum HL, et al. Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem.2006;98:139-51.
  35. Yirmiya R, Goshen I, Bajayo A, Kreisel T, Feldman S, Tam J, Tet al. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci U S A.2006;103:16876-81.
  36. Ortuño MJ, Robinson ST, Subramanyam P, Paone R, Huang YY, Guo XE, et al. Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect. Nat Med. 2016;22:1170.
  37. Nagareddy PR, Lakshmana M. Assessment of experimental osteoporosis using CT-scanning, quantitative X-ray analysis and impact test in calcium deficient ovariectomized rats. J Pharmacol Toxicol Methods.2005;52:350-5.
  38. Shapiro R, Heaney R. Co-dependence of calcium and phosphorus for growth and bone development under conditions of varying deficiency. Bone.2003;32:532-40.
Statistics
Article View: 373
PDF Download: 1,051